These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 34263961)

  • 1. Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.
    Infante M; Baidal DA; Rickels MR; Fabbri A; Skyler JS; Alejandro R; Ricordi C
    Artif Organs; 2021 Sep; 45(9):968-986. PubMed ID: 34263961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
    Haidar A; Tsoukas MA; Bernier-Twardy S; Yale JF; Rutkowski J; Bossy A; Pytka E; El Fathi A; Strauss N; Legault L
    Diabetes Care; 2020 Mar; 43(3):597-606. PubMed ID: 31974099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.
    Haidar A; Legault L; Matteau-Pelletier L; Messier V; Dallaire M; Ladouceur M; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):595-604. PubMed ID: 26066705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.
    Majdpour D; Tsoukas MA; Yale JF; El Fathi A; Rutkowski J; Rene J; Garfield N; Legault L; Haidar A
    Can J Diabetes; 2021 Dec; 45(8):734-742. PubMed ID: 33888413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of glucagon-like peptide-1 analogue versus amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm.
    Renukuntla VS; Ramchandani N; Trast J; Cantwell M; Heptulla RA
    J Diabetes Sci Technol; 2014 Sep; 8(5):1011-7. PubMed ID: 25030181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.
    Abitbol A; Rabasa-Lhoret R; Messier V; Legault L; Smaoui M; Cohen N; Haidar A
    Diabetes Technol Ther; 2018 Mar; 20(3):189-196. PubMed ID: 29393675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial.
    Wilson LM; Jacobs PG; Ramsey KL; Resalat N; Reddy R; Branigan D; Leitschuh J; Gabo V; Guillot F; Senf B; El Youssef J; Steineck IIK; Tyler NS; Castle JR
    Diabetes Care; 2020 Nov; 43(11):2721-2729. PubMed ID: 32907828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.
    Haidar A; Rabasa-Lhoret R; Legault L; Lovblom LE; Rakheja R; Messier V; D'Aoust É; Falappa CM; Justice T; Orszag A; Tschirhart H; Dallaire M; Ladouceur M; Perkins BA
    J Clin Endocrinol Metab; 2016 Jan; 101(1):214-23. PubMed ID: 26523526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Closing the Loop on Exercise in Type 1 Diabetes.
    Bally L; Thabit H
    Curr Diabetes Rev; 2018; 14(3):257-265. PubMed ID: 28245784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes technology and treatments in the paediatric age group.
    Shalitin S; Peter Chase H
    Int J Clin Pract Suppl; 2011 Feb; (170):76-82. PubMed ID: 21323816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors.
    Castle JR; El Youssef J; Wilson LM; Reddy R; Resalat N; Branigan D; Ramsey K; Leitschuh J; Rajhbeharrysingh U; Senf B; Sugerman SM; Gabo V; Jacobs PG
    Diabetes Care; 2018 Jul; 41(7):1471-1477. PubMed ID: 29752345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems.
    Peters TM; Haidar A
    Diabet Med; 2018 Apr; 35(4):450-459. PubMed ID: 29337384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current topics in glycemic control by wearable artificial pancreas or bedside artificial pancreas with closed-loop system.
    Hanazaki K; Munekage M; Kitagawa H; Yatabe T; Munekage E; Shiga M; Maeda H; Namikawa T
    J Artif Organs; 2016 Sep; 19(3):209-18. PubMed ID: 27142278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.
    Taleb N; Haidar A; Messier V; Gingras V; Legault L; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 Jan; 19(1):13-23. PubMed ID: 27629286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.